Clinical Trial Update: A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and feasibility of Toca 511, a retroviral replicating vector, in combination with the prodrug Toca FC in patients with recur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma

Drugs mentioned

• Toca 511 (retroviral replicating vector expressing cytosine deaminase)
• Toca FC (5-fluorocytosine)

Snippet

Sponsor: Tocagen Inc. | Conditions: Glioblastoma, Anaplastic Astrocytoma | Phase 1 | Status: COMPLETED